Recent events
Recent events tied to this brand in public sources.
Back to profile8 entries
2026
WuXi AppTec raises 2026 full-year guidance
WuXi AppTec announced that it had raised its 2026 overall revenue guidance from RMB 58.5–60.5 billion to RMB 61.0–61.9 billion, and its continuing-operations revenue growth guidance from 35–39% to 40–42%.
2026
WuXi AppTec discloses cybersecurity incident affecting DEL platform
WuXi AppTec announced on the evening of August 24 that its DNA-encoded library (DEL) platform under its biology business segment had recently suffered a cybersecurity incident. The company activated emergency response procedures, engaged external cybersecurity experts and legal counsel, and said its IT systems were operating normally and the DEL platform's security was under control, with no evidence found that data had been publicly disclosed, misused or improperly exploited. The company contacted affected biology business segment clients and said operations and service capability were unaffected.
2021
Megarobot completes a $65 million funding round
Megarobot announced that it had completed a new $65 million funding round led by an unnamed investor, with existing shareholders including WuXi AppTec and others also participating.
2021
WuXi AppTec completes acquisition of OXGENE
WuXi AppTec announced that it had completed its acquisition of OXGENE. OXGENE was to become a wholly owned subsidiary of WuXi Advanced Therapies, WuXi AppTec's cell and gene therapy business unit.
2020
Simcha raises $25 million
Simcha Therapeutics raised $25 million from WuXi AppTec, Sequoia Capital and Connecticut Innovations to advance its cytokine-engineering work.
2020
WuXi AppTec appoints David Chang to lead WuXi Advanced Therapies
WuXi AppTec announced the appointment of Dr. David Chang as Chief Executive Officer of its WuXi Advanced Therapies business unit.
2020
Canbridge Pharmaceuticals completes US$98 million Series D financing
Canbridge Pharmaceuticals announced that it had completed a US$98 million Series D financing. General Atlantic and WuXi AppTec led the round, and each had the right to make an additional investment of up to US$10 million subject to agreed conditions.
2019
WuXi AppTec receives 2019 Frost & Sullivan award
WuXi AppTec announced that it received Frost & Sullivan’s 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award.